$TSOI's journey has been nothing short of remarkable. Between June 2020 and February 2021, it was part of the surge in OTC stocks that reached unprecedented heights, defying expectations and leaving many in awe. However, the period following February 2021 has been marked by a puzzling series of events. Despite releasing over 50 press releases and showcasing its commitment to growth, the stock's price per share (PPS) has unexpectedly languished at 0013, a level that contradicts established trading norms and logical market practices.
Diverse opinions circulate regarding the nature of trading in the OTC market, with claims that a substantial portion—perhaps 90%—of companies are not authentic and are likely targets of nefarious tactics like naked short selling. In the case of $TSOI, it appears that these negative forces may have mistakenly targeted the company. This assumption gains strength when considering $TSOI's actions since February 2021. The company has diligently pursued innovation, securing over 80 intellectual property rights (IPs), of which more than 30 have been not only granted but also peer-published—a testament to the legitimacy of its endeavors.
Beyond its intellectual property successes, $TSOI has ambitiously ventured into the realm of clinical trials. Notably, it has unveiled a slew of Phase 3 clinical trials and eagerly anticipates progress on 5 new Investigational New Drug applications (INDs), poised to propel its Phase 2a/2b clinical trials forward. Amid these scientific advancements, $TSOI has found itself entangled in an Intellectual Property Rights (IPR) trial involving RESTEM LLC and JADICELLS LLC. In fact, the strategic partnership formed in February 2021 with JADICELLS, licensing their stem cell technology for lung and brain organ usage, is a key highlight.
The resilience of $TSOI shines through despite the adversities it has faced. The orchestrated decline in PPS, seemingly designed to stifle the company's fundraising efforts, prompted $TSOI to adopt a bold strategy: the creation of multiple subsidiaries. These subsidiaries, numbering more than half a dozen, have become receptacles for the transfer of matured intellectual property—a strategic move that has far-reaching implications.
Notably, recent developments indicate that $TSOI is charting a new course. The announcement of dividends in one subsidiary, Campbell Sciences LLC, and the promise of dividends in others, have piqued the interest of traders. This strategic maneuver has the potential to trigger a wave of positive sentiment as dividends find their way into trading accounts. The impending influx of dividends could serve as a catalyst, sparking renewed interest and encouraging traders to reinvest in $TSOI.
In conclusion, $TSOI's trajectory from soaring highs to its current state is a testament to its resilience and commitment to growth. The multifaceted approach, involving intellectual property acquisitions, clinical trial advancements, strategic partnerships, and the astute creation of subsidiaries, paints a picture of a company poised for resurgence. As dividends beckon and traders await, $TSOI stands at the threshold of a potentially transformative period, demonstrating that even in the face of adversity, strategic ingenuity and persistence can pave the way for renewed market success.
